Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NG 350A

Next Previous
Search
Drug Profile

NG 350A

Alternative Names: NG-350A

Latest Information Update: 16 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PsiOxus Therapeutics
  • Developer Akamis Bio; Cancer Research Institute; Parker Institute for Cancer Immunotherapy
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD40 antigen stimulants; Gene transference; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Carcinoma; Rectal cancer
  • No development reported Adenocarcinoma

Most Recent Events

  • 03 Apr 2025 Phase-I clinical trials in Rectal cancer (Late-stage disease, Combination therapy) in USA (IV) (NCT06459869)
  • 26 Feb 2025 Pharmacodynamic data from preclinical study in Cancer presented at the ESMO Targeted Anticancer Therapies Congress 2024 (TAT-2024)
  • 17 Dec 2024 NG 350A licensed to Xuanzhu Biopharma in China

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top